InMed Pharmaceuticals Inc. (IMLFF) Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755

InMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755&

 InMed Pharmaceuticals Inc. (IMLFF) Announces Completion of Initial Phase 1 Clinical Trial

InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN

InMed Pharmaceuticals Inc. (IMLFF) Reports Second Quarter Fiscal 2020 Financial Results

InMed Pharmaceuticals Reports Second Quarter Fiscal 2020 Financial Results

 InMed Pharmaceuticals Inc. (IMLFF) to Report Second Quarter Fiscal 2020 Financial Results

InMed Pharmaceuticals to Report Second Quarter Fiscal 2020 Financial Result

Marijuana Stocks Newsletter For September 3, 2019

TOP STORY: Inside Information on Marijuana Stocks What Did the Wolf Just&he

InMed Pharmaceuticals Inc. (IMLFF) to Present at the H.C. Wainwright 21st Annual Global Investment Conference

InMed Pharmaceuticals Inc. (“InMed” or the “Company”

InMed Pharmaceuticals Inc. (IMLFF) to Attend the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit

InMed Pharmaceuticals to Attend the 2nd Annual International Cannabinoid-De

InMed Pharmaceuticals Inc. (IMLFF) Reports Third Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update

InMed Pharmaceuticals Reports Third Quarter Fiscal 2019 Financial Results a

InMed Pharmaceuticals Inc. (IMLFF) to Report Third Quarter Fiscal 2019 Financial Results and Business Update on May 15, 2019

InMed Pharmaceuticals to Report Third Quarter Fiscal 2019 Financial Results

InMed Pharmaceuticals Inc. (IMLFF) to Present at the 31st Annual ROTH Conference on March 19, 2019

InMed Pharmaceuticals to Present at the 31st Annual ROTH Conference on Marc